We cannot quantify the precise in vivo contribution of CD8 T cells to the control observed and do not exclude a role for other subsets, particularly NK cells, in this patient, contributing either directly to anti–HIV-1 cytotoxicity or indirectly by conferring a clinical benefit against the patient's myeloma [34]. Here, CD8A is linked to plasma cell myeloma.